RJA
ICPT

Raymond James & Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Raymond James & Associates’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,435
Closed -$633K – 4250
2021
Q1 		$633K Buy
27,435
+17,031
+164% +$475K ﹤0.01% 2839
2020
Q4 		$257K Buy
+10,404
New +$345K ﹤0.01% 3230
2020
Q3 		– Sell
-64,829
Closed -$3.11M – 3722
2020
Q2 		$3.11M Sell
64,829
-43,992
-40% -$3.4M ﹤0.01% 1465
2020
Q1 		$6.85M Sell
108,821
-15,543
-12% -$1.4M 0.01% 897
2019
Q4 		$15.4M Buy
124,364
+16,420
+15% +$1.47M 0.02% 692
2019
Q3 		$7.16M Buy
107,944
+20,095
+23% +$1.35M 0.01% 1034
2019
Q2 		$6.99M Buy
87,849
+15,019
+21% +$1.34M 0.01% 1048
2019
Q1 		$8.15M Sell
72,830
-15,931
-18% -$1.74M 0.01% 923
2018
Q4 		$8.95M Buy
88,761
+10,550
+13% +$1.09M 0.02% 809
2018
Q3 		$9.88M Sell
78,211
-265
-0.3% -$28K 0.02% 834
2018
Q2 		$6.58M Buy
78,476
+324
+0.4% +$23.7K 0.01% 1032
2018
Q1 		$4.81M Buy
78,152
+44,079
+129% +$2.66M 0.01% 1175
2017
Q4 		$1.99M Buy
+34,073
New +$2.15M ﹤0.01% 1697
2017
Q2 		– Sell
-1,949
Closed -$220K – 3453
2017
Q1 		$220K Buy
+1,949
New +$228K ﹤0.01% 2880

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James & Associates's ICPT Position: Q2 2021 in Review

Raymond James & Associates sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 27,435 shares — an estimated $633K sold.

Raymond James & Associates first reported a position in ICPT in Q1 2017 and held it in 14 quarters. The position peaked at $15.4M in Q4 2019. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Raymond James & Associates reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 27,435 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $633K.
  • Raymond James & Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 14 quarters.
  • Raymond James & Associates's Intercept Pharmaceuticals, Inc. position peaked at $15.4M in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.